ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0069

Identification of CD13 as a Potential Cause for SARS-CoV-2-triggered Hyperinflammation and Thrombosis
Abstract Number: 0070

Neutrophils Transiting Through Megakaryocytes During Emperipolesis Exhibit Distinct Fates and Acquire the Capacity to Guide Other Neutrophils via MK Trails
Abstract Number: 0071

Significant Enrichment of Transcriptionally Distinct CD206+CD163+ Macrophage Population in Rheumatoid Arthritis Synovial Tissue
Abstract Number: 0072

Characterizing Heterogeneity of Synovial Macrophages in Rheumatoid Arthritis Patients
Abstract Number: 0073

A Cross-Species Map of Neutrophil Inflammatory Responses
Abstract Number: 0074

The Intracellular DNA Sensor STING Protects Against Bone Loss Through Regulation of Type I Interferons
Abstract Number: 0075

CD209+/CD14+ Dendritic Cells Characterization in Rheumatoid versus Psoriasis Arthritis Patients
Abstract Number: 0076

The Role of Interferon Kappa in Psoriasis
Abstract Number: 0077

Mimickers of Immunoglobulin G4-Related Disease
Abstract Number: 0078

Retrospective Analysis of Clinical Characteristics and Classification Criteria Performance in a Single Center Cohort of 114 Patients Diagnosed with IgG4-Related Disease
Abstract Number: 0079

Analysis of COVID-19 and Rheumatology Twitter Activity During the Pandemic Months
Abstract Number: 0080

Understanding Ankylosing Spondylitis –
Abstract Number: 0081

Prevalence of Systemic Autoimmune Diseases in Polycystic Ovary Syndrome
Abstract Number: 0082

Diffuse Sclerosing Osteomyelitis of the Jaw: An Underdiagnosed Disease in Maxillofacial Surgery Department
Abstract Number: 0083

Chronic Nonbacterial Osteomyelitis Is Associated with HLA-B*27

« Previous Page
1
…
5
6
7
8
9
…
139
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].